Pioneering cord blood transplantation in relapsed/refractory HIV-related lymphoma: A case study with concurrent intramuscular antiretroviral therapy.
HIV-related lymphoma
abotegravir
cord blood transplantation
rilpivirine
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
30
03
2024
revised:
23
05
2024
accepted:
30
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
A 44-year-old HIV-positive man diagnosed with diffuse large B-cell lymphoma in 2021 achieved complete remission with six cycles of R-CHOP therapy but had a relapse in November 2022. ESHAP therapy failed to induce remission, leading to complete remission with four cycles of Pola-BR therapy. Post-failure of autologous stem cell harvest, cord blood transplantation (CBT) was performed in June 2023. Notably, this case used recently approved intramuscular antiretroviral therapy (ART) with cabotegravir and rilpivirine, addressing gastrointestinal complications during CBT. This innovative use of intramuscular ART in the treatment of malignancy represents a first in the field, offering a pioneering approach to HIV-related lymphoma.
Identifiants
pubmed: 38838848
pii: S1201-9712(24)00195-4
doi: 10.1016/j.ijid.2024.107124
pii:
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107124Informations de copyright
Copyright © 2024. Published by Elsevier Ltd.